A.ErnstS
Efficacy and safety of ITCA 650, a novel drug-device GLP-1 receptor agonist, in Type 2 diabetes uncontrolled with oral antidiabetes drugs: the FREEDOM-1 trial
PlexusDx serves patients pursuing weight loss, metabolic health, and longevity without requiring a diabetes diagnosis
Market and Regulatory Pressure: Where the System Is Moving The rapid expansion of GLP-1 therapies has placed them at the center of market competition, regulatory scrutiny, and policy debate
Common Side Effects According to IVY RX's published safety information, commonly reported side effects include nausea, vomiting, stomach upset, abdominal pain, constipation, diarrhea, heartburn, excessive belching and gas, dizziness, headaches, and fatigue